GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surrozen Inc (NAS:SRZN) » Definitions » ROC (Joel Greenblatt) %

Surrozen (Surrozen) ROC (Joel Greenblatt) % : -790.93% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Surrozen ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Surrozen's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -790.93%.

The historical rank and industry rank for Surrozen's ROC (Joel Greenblatt) % or its related term are showing as below:

SRZN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -768.77   Med: -534.36   Max: -287.98
Current: -748.16

During the past 4 years, Surrozen's highest ROC (Joel Greenblatt) % was -287.98%. The lowest was -768.77%. And the median was -534.36%.

SRZN's ROC (Joel Greenblatt) % is ranked worse than
61.88% of 1469 companies
in the Biotechnology industry
Industry Median: -336.59 vs SRZN: -748.16

Surrozen's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Surrozen ROC (Joel Greenblatt) % Historical Data

The historical data trend for Surrozen's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surrozen ROC (Joel Greenblatt) % Chart

Surrozen Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-287.98 -523.80 -544.91 -768.77

Surrozen Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -120.82 -808.58 -681.42 -690.67 -790.93

Competitive Comparison of Surrozen's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Surrozen's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surrozen's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Surrozen's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Surrozen's ROC (Joel Greenblatt) % falls into.



Surrozen ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.978 + 0 + 2.947) - (4.015 + 0 + 0.225)
=0.685

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.152 + 0 + 2.937) - (4.359 + 0 + 0.292)
=0.438

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Surrozen for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-38.736/( ( (4.814 + max(0.685, 0)) + (3.858 + max(0.438, 0)) )/ 2 )
=-38.736/( ( 5.499 + 4.296 )/ 2 )
=-38.736/4.8975
=-790.93 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Surrozen  (NAS:SRZN) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Surrozen ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Surrozen's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Surrozen (Surrozen) Business Description

Traded in Other Exchanges
N/A
Address
171 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), and SZN-043 (E3/ASGR1, SWEETS).
Executives
Yang Li officer: Exec. Vice President, Research C/O SURROZEN, INC., 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Anna Berkenblit director 830 WINTER STREET, WALTHAM MA 02451
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Blutt Mitchell J Md director, 10 percent owner 1370 AVENUE OF THE AMERICA, SUITE 3301, NEW YORK NY 10019
Christopher Y Chai director 2400 BAYSHORE PARKWAY, SUITE 200, MOUNTAIN VIEW CA 94043
Mary Haak-frendscho director 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Wen-chen Yeh officer: Chief Scientific Officer 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
House Joshua Cory other: Former VP Business Development C/O CONSONANCE-HWF ACQUISITION CORP, 1 PALMER SQUARE, SUITE 305, PRINCETON NJ 08540
Geertrui Vanhove officer: Chief Medical Officer 1333 S. SPECTRUM BLVD #100, CHANDLER AZ 85286
Charles O Williams officer: Chief Financial Officer C/O HERITAGE FINANCIAL GROUP, 721 NORTH WESTOVER BOULEVARD, ALBANY GA 31707
Mace Rothenberg director 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Donald J Santel other: Former Director 4362 24TH STREET, SAN FRANCISCO CA 94114
David J Woodhouse director 630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Column Group Iii Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158

Surrozen (Surrozen) Headlines

From GuruFocus

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-04-2023

Surrozen Reports First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 06-30-2022